Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

AI-guided antibody designer BigHat taps J&J as latest partner as internal pipeline advances

Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs

April 24, 2024 12:03 PM UTC

A deal with J&J to create optimized antibodies for neurological disorders is the latest step in BigHat’s evolution as it moves its internal pipeline of AI-designed biologics toward the clinic.

The agreement with the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) is the fourth with a large pharma for BigHat Biosciences Inc., after deals with AbbVie Inc. (NYSE:ABBV), Amgen Inc. (NASDAQ:AMGN) and Merck & Co. Inc. (NYSE:MRK). Financial terms and targets are undisclosed...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article